Sign In
Section Navigation
Common TitleAPV29005
Official Title A 48 Week, Phase II, non-comparative, open-label, multi-cohort, multicenter study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of fosamprenavir (GW433908)/Ritonavir BID when administered to HIV-1 infected PI-Naive and experienced, Pediatric Subjects 2 to 18 years old and of fosamprenavir (GW433908) BID Administered to PI-Naive Pediatric subjects 2 to <6 years old
Phase Phase II
ClinicalTrials.gov NCT00089583
Categories PediatricsTreatment-Experienced
Funding
IndustryViiV Healthcare
References
  • Fortuny C, Duiculescu D, Cheng K, et al. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children. Pediatr Infect Dis J. 2014;33:50-6.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.